Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$6.32
$0.37(5.85%)
At close: 4:00 PM EDT
$6.32
$0.37(5.85%)
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous Close$6.69
Volume70.38K
Average Volume (3M)382.31K
Market Cap
$149.25M
Enterprise Value$52.64
Total Cash (Recent Filing)$73.87M
Total Debt (Recent Filing)$677.00K
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Nov 12, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,846
10 Day Avg. Volume240,671
30 Day Avg. Volume382,312
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside-16.93% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-3.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageMinimal debt reduces solvency pressure and interest obligations, giving the company more flexibility to fund development activities. This provides a useful financial cushion, although continued losses could gradually weaken that advantage.
Governance And Reporting ContinuityApproval of directors and the independent auditor supports continuity in oversight and financial reporting. Stable governance can help maintain execution discipline and stakeholder confidence while the company advances its development-stage operations.
Clinical And Financial Leadership RetentionRetaining senior financial and clinical leaders may preserve institutional knowledge and execution capacity during important development milestones. Leadership continuity is particularly valuable for a small biotech with only 40 employees and limited operating scale.
Bears Say
No Recorded Revenue And Widening LossesThe absence of revenue leaves the company dependent on future commercialization or partnering outcomes, while expanding losses show that operating costs are rising before revenue arrives. This limits operating leverage and keeps earnings risk elevated.
Heavy Cash Burn And Funding DependencePersistent and worsening cash consumption indicates substantial funding needs to sustain research and operations. Reliance on external capital can constrain strategic flexibility and may expose shareholders to future financing or dilution risk.
Erosion Of The Capital BaseThe decline in equity reflects the cumulative impact of ongoing losses and cash burn. If the trend continues without revenue or new capital, the company’s financial cushion may shrink, increasing pressure to secure funding on acceptable terms.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $149.25M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 80 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.874 by $0.214.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Overvalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,884,846 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.874. Following the earnings report the stock price went down -8.623%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.25 (-16.93% Downside)
$5.25 (-16.93% Downside)
Blogger Sentiment
Neutral
AARD Sentiment 100%
Sector Average 58%
Sector Average 58%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.76%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$5.25
▼(-16.93% Downside)
Technical Analysis
Ownership Overview
14.94% Insiders
4.47% Mutual Funds
27.25% Other Institutional Investors
49.93% Public Companies and
Individual Investors